ERBB3 and breast carcinoma: In parallel, emerging antigens such as HER3 [156], B7-H3 [157, 158], CEACAM5 [159, 160], TM4SF1 [161, 162], KIT [163, 164], and B7-H4[165, 166] have become focal points of current research, particularly in tumor types with limited treatment options, including genitourinary cancer, breast cancer, hepatopancreatobiliary (HPB) cancer, lung cancer, and neuroendocrine neoplasms (Fig. 4, Table 4).